- Home
- SPT vs RCUS Comparison
SPT vs RCUS Comparison
Compare SPT & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPT
- RCUS
- Stock Information
- Founded
- SPT 2010
- RCUS 2015
- Country
- SPT United States
- RCUS United States
- Employees
- SPT N/A
- RCUS N/A
- Industry
- SPT Computer Software: Prepackaged Software
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- SPT Technology
- RCUS Health Care
- Exchange
- SPT Nasdaq
- RCUS Nasdaq
- Market Cap
- SPT 799.3M
- RCUS 906.4M
- IPO Year
- SPT 2019
- RCUS 2018
- Fundamental
- Price
- SPT $15.19
- RCUS $10.53
- Analyst Decision
- SPT Buy
- RCUS Buy
- Analyst Count
- SPT 10
- RCUS 8
- Target Price
- SPT $27.70
- RCUS $20.71
- AVG Volume (30 Days)
- SPT 960.0K
- RCUS 810.6K
- Earning Date
- SPT 08-06-2025
- RCUS 08-06-2025
- Dividend Yield
- SPT N/A
- RCUS N/A
- EPS Growth
- SPT N/A
- RCUS N/A
- EPS
- SPT N/A
- RCUS N/A
- Revenue
- SPT $430,795,000.00
- RCUS $262,000,000.00
- Revenue This Year
- SPT $13.01
- RCUS N/A
- Revenue Next Year
- SPT $11.79
- RCUS $28.73
- P/E Ratio
- SPT N/A
- RCUS N/A
- Revenue Growth
- SPT 14.79
- RCUS 6.07
- 52 Week Low
- SPT $13.33
- RCUS $6.50
- 52 Week High
- SPT $36.30
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- SPT 40.96
- RCUS 62.68
- Support Level
- SPT $14.16
- RCUS $9.92
- Resistance Level
- SPT $15.11
- RCUS $10.75
- Average True Range (ATR)
- SPT 0.84
- RCUS 0.56
- MACD
- SPT 0.18
- RCUS 0.08
- Stochastic Oscillator
- SPT 45.59
- RCUS 77.83
About SPT Sprout Social Inc
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.